ASLAN ÇELEBI* MUJGAN GURLER**, DENIZ ÖGÜTMEN KOC*, ALI ABBAS OZDEMIR*, ISMAIL EKIZOGLU*, MURAT ALTAY*, SERIFE
*GaziosmanpaşaTaksim Education and Research Hospital, Department of Internal Medicine, Istanbul, Turkey - **Metin Sabanci Baltalimani Bone Disease Education and Research Hospital, Department of Internal Medicine, Istanbul, Turkey - ***Demre State Hospital, Department of Internal Medicine, Antalya, Turkey
Introduction: The present study aimed to compare serum visfatin levels among subjects with subclinical diabetes/pre-diabetes (impaired fasting glucose [IFG] alone and IFG+impaired glucose tolerance [IGT]), subjects with newly diagnosed type 2 diabetes mellitus (DM), and healthy nondiabeticnormoglycemic controls and to evaluate the relation of serum visfatin levels with some metabo- lic parameters and insulin resistance.
Materials and methods: The study was conducted in 80 subjects, of whom 52 (65%) were female and 28 (35%) were male. The subjects were divided into 4 groups as control, IFG, IFG+IGT, and newly diagnosed type 2 DM groups, containing 20 subjects in each. Waist and hip circumferences, age, gender, body mass index, and demographic characteristics were recorded in each group. The levels of fasting plasma glucose, fasting serum insulin, C-peptide, cortisol, glycosylated hemoglobin (HbA1c), total cholesterol, high- density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL- C), triglyceride were measured and insulin/C-peptide ratio and the homeostasis model assessment-insulin resistance (HOMA-IR) were calculated and compared among the groups.
Results: In line with glucose metabolism disorder, significant increases were observed in the insulin, C-peptide, insulin/C-pepti- de ratio, HbA1c (%), HOMA-IR values, cardiovascular risk parameters (total cholesterol, LDL-C, VLDL-C, triglyceride), and visfatin levels in the subclinical diabetes and diabetes groups as compared to the control group.
Conclusion: Visfatin could be considered among therapeutic agents used in the prevention of diabetes and in the prevention or reduction of its critical complications.
Subclinical diabetes mellitus, type 2 diabetes mellitus, visfatin.